A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response While Receiving Telaprevir, Peginterferon Alfa2a (Pegasys) and Ribavirin (Copegus).

Trial Profile

A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response While Receiving Telaprevir, Peginterferon Alfa2a (Pegasys) and Ribavirin (Copegus).

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2015

At a glance

  • Drugs Peginterferon alfa-2a; Ribavirin; Telaprevir
  • Indications Hepatitis C
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ILLUMINATE
  • Most Recent Events

    • 15 Sep 2011 Results reported in a Vertex Pharmaceuticals media release and published in the New England Journal of Medicine.
    • 20 Jul 2011 Actual initiation date is Oct 2008 added as reported by ClinicalTrials.gov.
    • 25 May 2011 Work productivity results presented at the 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top